Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate

Condition:   Asthma
Interventions:   Drug: Fluticasone / Salmeterol;   Drug: Placebo;   Drug: Advair Diskus 100/50
Sponsors:   Roxane Laboratories;   Vectura Limited
Completed – verified January 2016

View full post on ClinicalTrials.gov: asthma | received in the last 14 days